Supernus SVP reports RSU vesting, tax withholding

SUPERNUS PHARMACEUTICALS, INC. senior vice president Frank Mottola reported routine equity compensation activity.

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. senior vice president Frank Mottola reported routine equity compensation activity. On February 25, 2026, 1,875 restricted stock units were disposed of to the issuer and simultaneously settled into 1,875 shares of common stock as part of a vesting event.

In a separate transaction the same day, 977 shares of common stock were disposed of through a tax-withholding disposition at $50.69 per share to satisfy withholding obligations tied to the RSU vesting. After these transactions, Mottola directly owned 18,106 shares of common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Mottola Frank

Role SVP, Chief Tech. Ops. Officer

Type	Security	Shares	Price	Value
Disposition	Restricted Stock Unit	1,875	$0.00	$0.00
Grant/Award	Common Stock	1,875	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	977	$50.69	$50K

Holdings After Transaction: Restricted Stock Unit — 1,875 contracts (Direct); Common Stock — 18,106 shares (Direct)

Footnotes (3)

1. F1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
2. F2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
3. F3. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SUPN executive Frank Mottola report on February 25, 2026?

Frank Mottola reported disposition of 1,875 restricted stock units to the issuer and acquisition of 1,875 common shares from vesting, plus a tax-withholding disposition of 977 shares at $50.69 per share, leaving him with 18,106 directly owned shares.

How many Supernus (SUPN) shares does Frank Mottola own after these Form 4 transactions?

Following the reported transactions, Frank Mottola directly owns 18,106 shares of Supernus common stock. This figure reflects the RSU vesting into 1,875 shares and the tax-withholding disposition of 977 shares used to cover related withholding obligations.

Was the 977-share Supernus (SUPN) transaction an open-market sale by Frank Mottola?

No, the 977-share transaction was a tax-withholding disposition at $50.69 per share. The shares were withheld by the company to satisfy tax withholding requirements related to the restricted stock unit vesting, rather than sold in an open-market transaction.

How do Frank Mottola’s restricted stock units in SUPN convert into common stock?

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. These units are settled in common stock in four equal annual installments, beginning on February 23, 2024, according to the disclosed vesting schedule.

What is the vesting schedule for Frank Mottola’s Supernus (SUPN) restricted stock units?

The restricted stock units vest in four equal annual installments, beginning on February 23, 2024. Upon each vesting date, RSUs are settled in shares of Supernus common stock, with some shares potentially withheld to cover tax withholding obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mottola Frank

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Tech. Ops. Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		A		1,875	A	$0	19,083	D
Common Stock	02/25/2026		F		977(1)	D	$50.69	18,106	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	02/25/2026		D			1,875	(3)	(3)	Common Stock	1,875	$0	1,875	D

Explanation of Responses:

1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.

2. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

3. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.